Tanox, Inc. To Present At JP Morgan Healthcare Conference

HOUSTON, Jan. 4 /PRNewswire-FirstCall/ -- Tanox, Inc. will be one of the presenting companies at the 24th annual JP Morgan Healthcare Conference to be held Jan. 9-12, 2006 in San Francisco.

Tanox Vice President of Strategy and Corporate Development, Danong Chen and Medical Director Dr. Stanley Lewis will present at the conference Wednesday, Jan. 11, at 8:30 a.m., PST. Chen, who will transition into the role of Tanox president and chief executive officer effective Feb. 1, and Lewis will discuss 2006 objectives, the status of the company's drug development pipeline and provide an overview of TNX-355, a novel viral-entry inhibitor antibody to treat HIV/AIDS.

A live webcast of the presentation will be accessible from the Investor Relations section on the company's Web site at http://www.tanox.com . Presentation slides will be available on the site following the live address.

About Tanox, Inc.

Tanox is a biotechnology company specializing in the discovery and development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiretroviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com .

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGOPRN Photo Desk,photodesk@prnewswire.comTanox, Inc.

CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, orssievert@tanox.com

Back to news